Medical Marijuana has a problem with waste and inefficency when it comes to extracting from a marijuana plant.
Currently only about 2% of the cannabis plant can be exploited using extraction techniques. Factor in the cost to grow and problems with consistency in the growing process and you can see why we say there is a problem with inefficiency.
Most of the time is spent extracting THC and CBD, just two of the over 90+ suspected and known cannabinoids in the plant. Imagine if there was an easier way to utilize the other cannabinoids. Think of what that could do to the medical market.
Today we saw a company take a major step towards solving the inefficiency problem, which could also put billions of dollars into play.
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the
research and development of novel, cannabinoid-based drug therapies, today announces the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.
The patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions throughout the world, will provide significant commercial protection for InMed’s E. coli-based expression system to manufacture any of the 90+ cannabinoid compounds that may have a medical impact on important human diseases.
THIS IS HUGE! InMed just filed a patent on their proprietary biosynthesis process that can manufacture any of the medical cannabinoid compounds... without ever touching the plant!!
InMed provisional-patent filing demonstrates their confidence that their biosynthetic capability not only captures the superior economics of bypassing the grow-harvest-extract-purify cycle, but is also vastly more scalable and amenable to long-term systems optimization.
InMed is now poised to do to cannabis medicine what Ely Lilly did back in the early 1980s to the then insulin manufacturing industry.
Namely, transforming an entire industry through biosynthetics and creating a billion dollar plus business.
InMed’s approach here is the best of both worlds really, combining the safety and efficacy of naturally occurring phytocannabinoid molecular structures, with a truly 21st Century production process that also opens the door to a host of promising minor cannabinoids which are not commercially viable to extract from plant sources.
This will be the first in a series of patent applications directed to various aspects of the Company’s biosynthesis program. In particular, these applications focus on the superior nature of E. coli-based expression systems over other approaches; gene optimization for maximizing the production of cannabinoids and related compounds; and other proprietary developments and data. The company will actively convert this and subsequent provisional patents into national-stage filings in all major commercial jurisdictions, in due course.
InMed’s cannabinoid biosynthesis program is one of three core assets, which also include the bioinformatics assessment tool to target specific cannabinoids against important diseases, as well as the drug development program, which includes INM-750 for Epidermolysis bullosa and INM-085 for glaucoma.
“This novel approach to the biosynthesis of cannabinoids is a game-changer for drug
development. The importance of producing cannabinoids that are identical to the naturally
occurring compounds cannot be overstated. Many drug development efforts with synthetic
derivatives have failed,”
Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at University of British Columbia, a co-inventor of the biosynthesis
“In our extensive experimentation, the E. coli system is more robust and more
efficient for the manufacturing of cannabinoids as compared to other microbial platforms.”
The PCT is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member states. There are 151- member countries within the PCT, enabling near global patent coverage through successful patent prosecution in the U.S., Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, India and many other countries.
This is massive news for investors who want to get in early on a company poised for stratospheric growth. Right now InMed is under valued and under the radar, but with this announcement it might not stay that way for long.
InMed is a preclinical stage biopharmaceutical company specializing in the research and
development of novel, cannabinoid-based prescription drug therapies utilizing novel drug
delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory,
manufacturing and commercial development activities for its product candidates. InMed’s
proprietary bioinformatics database assessment tool, the biosynthesis manufacturing
process and its drug development programs are the fundamental value drivers of the
For more information, visit www.inmedpharma.com
For the Full Release please click here.